Summary
A Nature Medicine editorial says WHO’s first treatment guidelines for obesity in children and adolescents highlight weak evidence for both medicines and lifestyle interventions. It calls for research that better reflects young people’s living conditions and follows treatment effects over time.
A Nature Medicine editorial published on 12 November 2026 argues that care for children and adolescents with obesity needs a stronger evidence base. It points to the World Health Organization’s first treatment guidelines for these age groups, released on 7 October 2026, and says they expose major gaps in what is known about both medicines and more traditional interventions such as diet and exercise.
The WHO guidelines do not recommend pharmacological treatment, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), for children. For adolescents aged 10–19, they recommend pharmaceutical treatment only after other options have been exhausted. The editorial reports that the evidence supporting pharmacotherapy is rated low, while evidence for traditional weight-loss interventions is rated very low.
Why the evidence needs to reflect everyday life
The editorial describes youth obesity as a growing health concern: it cites a rise in the share of adolescents worldwide who are overweight, from 8% in 1990 to 20% in 2024. It also notes that obesity in adolescence often continues into adulthood, citing an estimate that 70% of adolescents with obesity still have obesity at age 30. The consequences can include longer-term conditions such as type 2 diabetes, as well as immediate risks including asthma and hypertension. The editorial also points to stigma and its effects on mental health and educational attainment.
Its central argument is that interventions must account for the conditions in which young people live. Exercise advice is harder to act on where safe, accessible space is scarce; the editorial gives dense urban environments with limited exercise areas and high air pollution as examples. Dietary advice also depends on whether families can afford and access healthier food. Because children may not control what food is available at home or school, the editorial says interventions should involve parents, guardians or teachers who shape their diets.
This matters for study design as well as service delivery. Trials conducted in controlled settings may not capture the barriers young people face outside them. The editorial calls for exercise research that better reflects real-world environments and for dietary approaches that account for food access and the adults responsible for children’s meals.
Questions around medicines in adolescence
The editorial says GLP-1RAs could benefit some young people, but evidence in children and adolescents is limited. It argues that studies need to assess safety as well as efficacy, with long-term follow-up to understand whether treatment affects development during puberty.
It also highlights questions about stopping treatment. The editorial notes evidence that adults may regain weight after discontinuing GLP-1RAs, raising the possibility that some treatment could continue for a long time. How young people might manage weight if they later stop medication is therefore an important research and care-planning issue. The editorial presents this as a concern to investigate, not an established outcome for children.
The piece’s broader case is that treatment recommendations need evidence suited to young people’s circumstances and stages of development. Better studies could help clinicians and health systems assess which approaches work, for whom, and under what conditions.